BiotechTube
Home/PeLeMed/Soo Jin Kim
SJ

Soo Jin Kim

Executive Director, Global Innovative Drug Discovery & Development

PeLeMed

Therapeutic Areas

OncologyInfectious Diseases

PeLeMed Pipeline

DrugIndicationPhase
PLD-102FLT3‑mutant AMLPhase 1
PLD-103YAP‑TEAD driven cancersPreclinical
PLD-104RET‑mutant NSCLCPreclinical
PLD-105PD‑1 non‑responding solid tumorsPreclinical
PLD-106Renal cell carcinoma & hepatocellular carcinomaPreclinical
PLD-107ADC for AML & solid tumorsPreclinical
PLM-401/402Chronic hepatitis B virusPreclinical

Leadership Team at PeLeMed

YK
Yong‑Chul Kim
CEO/CTO
SY
Soo Yeon Jang
CEO
JH
Jong Hyeok Park
CFO
MM
Miran Moon
Executive Director, Global Clinical Development and Strategy
View full PeLeMed profile